Skip to main content

Table 3 Use of antidiabetic drugs and the risk of thyroid cancer restricted to cases and controls with a recorded diagnosis of diabetes mellitus

From: No evidence for a decreased risk of thyroid cancer in association with use of metformin or other antidiabetic drugs: a case-control study

Drugs and No. prescriptions

Cases (%) (n = 70)

Controls (%) (n = 419)

Crude OR (95 % CI)

Adjusted OR (95 % CI) model 1a

Adjusted OR (95 % CI) model 2b

Metformin

 No prior use

23 (32.9)

165 (39.4)

1.00 (referent)

1.00 (referent)

1.00 (referent)

 Any use

47 (67.1)

254 (60.6)

1.40 (0.78–2.49)

1.30 (0.68–2.47)

1.42 (0.74–2.73)

 1–29

21 (30.0)

129 (30.8)

1.21 (0.61–2.39)

1.18 (0.57–2.45)

1.28 (0.61–2.67)

 ≥30

26 (37.1)

125 (29.8)

1.60 (0.83–3.09)

1.48 (0.69–3.18)

1.67 (0.76–3.67)

Sulfonylurea

 No prior use

32 (45.7)

231 (55.1)

1.00 (referent)

1.00 (referent)

1.00 (referent)

 Any use

38 (54.3)

188 (44.9)

1.48 (0.88–2.48)

1.51 (0.83–2.75)

1.46 (0.78–2.72)

 1–29

19 (27.1)

97 (23.2)

1.43 (0.76–2.67)

1.56 (0.79–3.10)

1.52 (0.76–3.07)

 ≥30

19 (27.1)

91 (21.7)

1.53 (0.81–2.89)

1.41 (0.68–2.94)

1.35 (0.62–2.90)

Insulin

 No prior use

52 (74.3)

349 (83.3)

1.00 (referent)

1.00 (referent)

1.00 (referent)

 Any use

18 (25.7)

70 (16.7)

1.83 (0.98–3.42)

1.94 (0.97–3.88)

1.84 (0.90–3.76)

TZD

 No prior use

61 (87.1)

366 (87.4)

1.00 (referent)

1.00 (referent)

1.00 (referent)

 Any use

9 (12.9)

53 (12.7)

1.03 (0.45–2.33)

0.80 (0.33–1.92)

0.66 (0.26–2.90)

  1. OR odds ratio, CI confidence interval
  2. aModel 1 adjusted for all antidiabetic drugs in the table, BMI, smoking, and diabetes duration
  3. bModel 2 adjusted for all antidiabetic drugs in the table, BMI, smoking, diabetes duration, hyperthyroidism, and goiter